No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PRVA Privia Health
- 19.095
- -0.075-0.39%
Trading Jul 22 11:09 ET
2.28BMarket Cap127.30P/E (TTM)
19.345High18.955Low147.47KVolume19.280Open19.170Pre Close2.82MTurnover0.16%Turnover Ratio100.50P/E (Static)119.32MShares28.10052wk High3.95P/B1.81BFloat Cap15.92052wk Low--Dividend TTM94.80MShs Float50.770Historical High--Div YieldTTM2.03%Amplitude15.920Historical Low19.129Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Take Care Before Diving Into The Deep End On Privia Health Group, Inc. (NASDAQ:PRVA)
With a median price-to-sales (or "P/S") ratio of close to 1.1x in the Healthcare industry in the United States, you could be forgiven for feeling indifferent about Privia Health Group, Inc.'s (
Privia Health to Report Second Quarter 2024 Results on Thursday, August 8
ARLINGTON, Va., July 11, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it plans to release financial results for its second quarter and six-month periods
Forecasting The Future: 7 Analyst Projections For Privia Health Gr
Analysts' ratings for Privia Health Gr (NASDAQ:PRVA) over the last quarter vary from bullish to bearish, as provided by 7 analysts.In the table below, you'll find a summary of their recent ratings,
Express News | Evercore ISI Group Maintains Outperform on Privia Health Gr, Lowers Price Target to $20
Should Weakness in Privia Health Group, Inc.'s (NASDAQ:PRVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Privia Receives HFMA's MAP Award for High Performance in Revenue Cycle for Performance Year 2023
Privia Health has received the HFMA MAP Award in eight of the past nine yearsARLINGTON, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of
Comments
Jefferies analysts predict a shift to value-based care as a defining trend in healthcare. They foresee Astrana Health's unique model gaining attention, closing the valuation gap with popular peers. Privia is also praised for its balanced, sustainable earnings growth.
Jefferies Cautious on Value Based Care Providers; Favors ASTH, PRVA, TOIPrivia Health's CEO, Parth Mehrotra, welcomes Edward C. Fargis, citing his vast experience in corporate governance, compliance and strategic transactions. Fargis is eager to contribute to a profitable growth strategy benefiting stakeholders.
1 | Below is a look at the top insider trades with the biggest value in the past week.
The largest insider trading of this week, which is a sale order of 24,819,473 units, worth over $536.47M, was made by Privia Health director, Daniel Jeffrey Bernstein, on May 10, 2023.
In total, Daniel has made about 4 transactions worth about $1.04B over 2 years at Privia Health Group. The current estimated net worth of Privi...
The largest insider trading of this week, which is a sale order of 24,819,473 units, worth over $536.47M, was made by Privia Health director, Daniel Jeffrey Bernstein, on May 10, 2023.
In total, Daniel has made about 4 transactions worth about $1.04B over 2 years at Privia Health Group. The current estimated net worth of Privi...
13
2
Gapping up
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
9
Upgrades
• $Agora(API.US$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $12.50
• $argenx SE(ARGX.US$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $375 (from $278)
• $Idacorp(IDA.US$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $110 (from $108)
• $Jakks Pacific(JAKK.US$ : BMO Capital Upgrades to Outperform from Market Perform - PT $21
• $Coca-Cola FEMSA(KOF.US$ : Barclays Upgrades to Overweight from Equal Wei...
• $Agora(API.US$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $12.50
• $argenx SE(ARGX.US$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $375 (from $278)
• $Idacorp(IDA.US$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $110 (from $108)
• $Jakks Pacific(JAKK.US$ : BMO Capital Upgrades to Outperform from Market Perform - PT $21
• $Coca-Cola FEMSA(KOF.US$ : Barclays Upgrades to Overweight from Equal Wei...
12
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg